Artificial Intelligence for Histopathological Classification and Recurrence Prediction of Thymic Epithelial Tumors

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histopathological classification. In this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses. The investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence. In this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation. The ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.

Eligibility
Participation Requirements
Sex: All
View:

⁃ Participants with specific diagnoses are eligible for inclusion in the study. The eligible diagnoses include various subtypes of thymoma and thymic carcinoma, specifically:

• Thymoma A

• Thymoma AB

• Thymoma B1

• Thymic Carcinoma

⁃ Inclusion is based on a consensus diagnosis with a level of agreement less than 70%. This criterion is applied during the training phase of the model.

⁃ Recurrence Criteria:

⁃ Participants with a documented recurrence outcome within a 5-year period are considered eligible for this aspect of the study. This criterion is primarily applied during the validation phase.

Locations
Other Locations
Netherlands
Erasmus MC
RECRUITING
Rotterdam
Contact Information
Primary
Anna Salut Esteve Domínguez
a.estevedominguez@erasmusmc.nl
0107043491
Time Frame
Start Date: 2023-08-01
Estimated Completion Date: 2027-08-01
Participants
Target number of participants: 1020
Treatments
Patients with TET
Patients diagnosed with the following TET subtypes:~* Thymoma Type A~* Thymoma Type AB~* Thymoma Type B1~* Thymoma Type B2~* Thymoma Type B3~* Thymic Carcinoma
Recurrence
Patients with thymic epithelial tumors who have experienced recurrence.
Related Therapeutic Areas
Sponsors
Collaborators: Hospices Civils de Lyon, Maastro Clinic, The Netherlands
Leads: Erasmus Medical Center

This content was sourced from clinicaltrials.gov